Literature DB >> 30005040

Solitary Plasmacytoma of Bone of the Spine: Results From Surveillance, Epidemiology, and End Results (SEER) Registry.

Yufu Wang1, Hui Li1, Chao Liu1, Chao Chen2, Jinglong Yan1.   

Abstract

STUDY
DESIGN: Retrospective analysis.
OBJECTIVE: To determine the prognostic indicators in patients with solitary plasmacytoma of bone (SPB) of the spine. SUMMARY OF BACKGROUND DATA: Population-level estimates for prognosis among patients with SPB of the spine are still lacking. Sociodemographic and clinical predictors of outcome have not been well characterized.
METHODS: The Surveillance, Epidemiology, and End Results Registry was used to identify all patients with SPB of the spine from 1995 through 2014. Associated population data were used to determine annual incidence and limited-duration prevalence. Overall survival (OS) estimates were obtained using the Kaplan-Meier method and compared across groups using log-rank test. A Cox regression model was used for multivariate analysis of survival. Logistic regression was performed to identify predictors of the progression to multiple myeloma (MM).
RESULTS: The incidence and prevalence of the disease increased during the study period. Spinal SPB most commonly affected older people (>50) with a male preponderance. The median OS were 74.0 months. The 5 and 10-year survival rates for these patients were 56.1% and 36.7%, respectively. On multivariable analyses, older age, and surgery without radiotherapy were correlated with poor survival of patients with spinal SPB. The 3-year probability of progression to MM was 10.1%. Patients aged >70 years were associated with progression to MM. There was no significant association between the methods of surgical resection (radical or local/partial) and OS or progression to MM.
CONCLUSION: The findings of this study provide population-based estimates of the incidence, prevalence and prognosis for patients with SPB of the spine. This analysis indicated that the only identifiable prognostic indicators were older age and surgery without radiotherapy. Moreover, the methods of surgical resection did not influence the OS or progression to MM. LEVEL OF EVIDENCE: 4.

Entities:  

Mesh:

Year:  2019        PMID: 30005040     DOI: 10.1097/BRS.0000000000002777

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  6 in total

1.  Surgical efficacy and survival prediction of patients with unspecified malignant bone tumors.

Authors:  Shaohui He; Runyi Jiang; Haitao Sun; Jian Yang; Chen Ye; Weibo Liu; Xinghai Yang; Xiaopan Cai; Jianru Xiao
Journal:  BMC Cancer       Date:  2022-10-20       Impact factor: 4.638

2.  Prognostic Nomogram for Predicting Overall Survival of Solitary Bone Plasmacytoma Patients: A Large Population-Based Study.

Authors:  Gong Feng; Wu-Bin Shu; A-Bing Li
Journal:  Int J Gen Med       Date:  2021-11-23

3.  Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia.

Authors:  Lea Baumgart; Melanie Barz; Claire Delbridge; Amir Kaywan Aftahy; Insa Katrin Janssen; Philipp J Jost; Yu-Mi Ryang; Bernhard Meyer; Jens Gempt
Journal:  Curr Oncol       Date:  2022-08-29       Impact factor: 3.109

4.  Prognosis of solitary bone plasmacytoma of the extremities: A SEER-based study.

Authors:  Renbo Zhao; Zhaoxin Chen; Sujun Zhao; Yali Cheng; Xiaobo Zhu
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

5.  Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis.

Authors:  Khaled Elsayad; Michael Oertel; Laila König; Sebastian Hüske; Emmanuelle Le Ray; Mohamed A M Meheissen; Amr Abdelaziz Elsaid; Essam Elfaham; Jürgen Debus; Youlia Kirova; Klaus Herfarth; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2020-03-13       Impact factor: 6.639

6.  Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population-based study.

Authors:  Xuxing Shen; Shu Liu; Chao Wu; Jing Wang; Jianyong Li; Lijuan Chen
Journal:  Cancer Med       Date:  2020-11-03       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.